**Supplementary Table 1. Multivariate logistic regression analysis of risk factors predicting advanced fibrosis in MAFLD patients between the study periods of 2009–2014 and 2015–2020**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Factors** | **FIB-4** |  | **Crude** | **Adjusted**  |
| **2009–2014 (*n* = 897)** | **≤ 3.25, *n* = 852** | **> 3.25, *n* = 45** | **OR****(95% CI)** | ***p*-value** | **OR****(95% CI)** | ***p-*value** |
| Age (years) | 51.4 ± 12.9 | 58.1 ± 13.5 | 1.04 (1.01–1.07) | 0.0009\* | 1.04 (1.01–1.07) | 0.006\* |
| Female | 519 (95.4) | 25 (4.6) | 0.8 (0.44–1.48) | 0.476 | 0.69 (0.36–1.31) | 0.26 |
| Male | 333 (94.3) | 20 (5.7) | 1 |  | 1 |  |
| MAFLD phenotype |  |  |  |  |  |  |
| BMI ≤ 23 kg/m2 and ≥ 2 metabolic items | 22 (78.6) | 6 (21.4) | 6.07 (2.13–15.16) | 0.002\* | 4.71 (1.65–13.41) | 0.004\* |
| ≤ 23 kg/m2 and < 2 metabolic items  | 67 (93.1) | 5 (6.9) | 1.66 (0.56–4.04) | 0.333 | 1.32 (0.45–3.84) | 0.61 |
| > 23 kg/m2 | 757 (95.7) | 34 (4.3) | 1 |  | 1 |  |
| T2DM, Yes | 154 (95.1) | 8 (4.9) | 0.98 (0.42–2.4) | 0.957 | 0.99 (0.43–2.28) | 0.98 |
|  No | 697 (95.0) | 37 (5.0) | 1 |  | 1 |  |
| HBsAg+/anti-HCV+  | 10 (71.4) | 4 (28.6) | 18.06 (4.51–62.44) | 0.0003\* | 17.70 (4.66–67.28) | < 0.001\* |
| Anti-HCV+ | 81 (83.5) | 16 (16.5) | 8.92 (4.15–19.54) | < 0.0001\* | 7.66 (3.46–17.00) | < 0.001\* |
| HBsAg+ | 174 (93.6) | 12 (6.4) | 3.11 (1.38–6.99) | 0.007 | 3.86 (1.67–8.90) | 0.002\* |
| HBsAg-/anti-HCV- | 587 (97.8) | 13 (2.2) | 1 |  | 1 |  |

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **2015–2020 (*n* = 1,051)** | **≤ 3.25, *n* = 1017** | **> 3.25, *n* = 34** | **OR****(95% CI)** | ***p*-value** | **OR****(95% CI)** | ***p*-value** |
| Age (years) | 50.8 ± 13.5 | 64.8 ± 9.8 | 1.09 (1.06–1.13) | < 0.001\* | 1.08 (1.05–1.12) | < 0.001\* |
| Female | 452 (96.0) | 19 (4.0) | 1.58 (0.80–3.15) | 0.19 | 1.25 (0.59–2.63) | 0.56 |
| Male | 565 (97.4) | 15 (2.6) | 1 |  | 1 |  |
| MAFLD phenotype1 |  |  |  |  |  |  |
| BMI ≤ 23 kg/m2 | 21 (87.5) | 3 (12.5) | 4.59 (1.30–16.20) | 0.02\* | 4.37 (1.05–18.17) | 0.04\* |
| > 23 kg/m2 | 996 (97.0) | 31 (3.0) | 1 |  | 1 |  |
| T2DM, Yes | 225 (96.6) | 8 (3.4) | 1.08 (0.48–2.43) | 0.85 | 0.62 (0.26–1.48) | 0.28 |
|  No | 792 (96.8) | 26 (3.2) | 1 |  | 1 |  |
| Anti-HCV+1 | 74 (80.4) | 18 (19.6) | 14.87 (7.11–31.10) | < 0.001\* | 9.91 (4.58–21.42) | < 0.001\* |
| HBsAg+ | 87 (97.8) | 2 (2.2) | 1.41 (0.31–6.29) | 0.66 | 2.01 (0.44–9.33) | 0.37 |
| HBsAg-/anti-HCV- | 856 (98.4) | 14 (1.6) | 1 |  | 1 |  |

There were no subjects with HBV/HCV coinfection or BMI ≤ 23 kg/m2 and < 2 metabolic items. Data are means ± standard deviation or *n* (%).

BMI, body mass index; CI, confidence interval; FIB-4, fibrosis-4 index; MAFLD, metabolic dysfunction-associated fatty liver disease; OR, odds ratio; T2DM, type 2 diabetes.